1. Anti-infection
  2. Bacterial

Squalamine (Synonyms: MSI-1256)

Cat. No.: HY-16468 Purity: >98.0%
Data Sheet SDS Handling Instructions

Squalamine(MSI-1256) is an aminosterol compound with potent broad spectrum antiviral activity.

For research use only. We do not sell to patients.
Squalamine Chemical Structure

Squalamine Chemical Structure

CAS No. : 148717-90-2

Size Price Stock Quantity
10 mM * 1 mL in DMSO $1312 In-stock
1 mg $500 In-stock
5 mg $950 In-stock
10 mg $1600 In-stock
50 mg $5000 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


Squalamine(MSI-1256) is an aminosterol compound with potent broad spectrum antiviral activity. IC50 value: Target: in vitro: squalamine can strongly displace membrane-bound cationic proteins such as Rac1, a ρ-GTPase recruited to the inner leaflet of the eukaryotic cytoplasmic membrane for the actin remodeling necessary for endocytosis. At concentrations between 20 and 60 μg/mL, squalamine has been shown to inhibit a broad array of growth factor-induced, actin-dependent responses in endothelial cells, including cell migration, cell division, and vascular tube formation in a 3D matrix [1]. Squalamine effectively inhibited HBV replication in human primary hepatocytes when added either during the initial exposure of virus to the cells or at 24 h after infection. A similar study was performed to evaluate the effect of squalamine on the replication of HDV. Squalamine was introduced at 20 μg/mL during HDV exposure, and the effects were measured at day 7 when total RNA was extracted and assayed for HDV RNA sequences [1]. in vivo: one time daily treatment with squalamine (15 or 30 mg/kg per d s.c.) was started beginning on day 1 or 2 after viral administration and continuing until day 8 or 9, respectively. Survival was monitored, and animals that remained alive by day 21 were considered cured [1].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT00094120 Genaera Corporation Macular Degeneration October 2004 Phase 2
NCT00333476 Genaera Corporation Macular Degeneration May 2006 Phase 2
NCT00089830 Genaera Corporation Macular Degeneration August 2004 Phase 2
NCT02349516 Starr Muscle|Ohr Pharmaceutical Inc.|NJ Retina Diabetic Retinopathy February 2015 Phase 2
NCT02511613 Ohr Pharmaceutical Inc. Age-Related Macular Degeneration July 2015 Phase 2
NCT02614937 Ohr Pharmaceutical Inc.|Cumberland Valley Retina Consultants, PC Retinal Vein Occlusion|Macular Edema April 2013 Phase 1|Phase 2
NCT00139282 Genaera Corporation Wet Age-Related Macular Degeneration June 2005 Phase 3
NCT00021385 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Ovarian Cancer May 2001 Phase 2
NCT01678963 Ohr Pharmaceutical Inc. Neovascular Age Related Macular Degeneration November 2012 Phase 2
NCT02727881 Ohr Pharmaceutical Inc. Age-related Macular Degeneration April 12, 2016 Phase 3
NCT00244920 OHSU Knight Cancer Institute|National Cancer Institute (NCI) Prostate Cancer January 2002 Phase 2
NCT01769183 Elman Retina Group Retinal Neovascularization February 2013 Phase 2
View MoreCollapse
Molecular Weight






Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility


* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: